Pirarubicin

Drug Profile

Pirarubicin

Alternative Names: 1609RB; Pinorubin; Tetrahydropyranyl doxorubicin; Theprubicina; Theprubicine; Therarubicin; THP

Latest Information Update: 16 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Almirall S.A.; CSL Behring; Meiji Seika Pharma; Mercian; Nippon Kayaku; Sanofi; sanofi-aventis
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action DNA topoisomerase inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Breast cancer; Cancer

Most Recent Events

  • 08 Jan 2007 ZLB Behring is now called CSL Behring
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 01 Apr 2004 Aventis Behring LLC has merged with ZLB Bioplasma to form ZLB Behring
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top